MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zearo, Silvia ^a   Kim, Edward ^a   Zhu, Ying ^b   Zhao, Jing T ^a   Sidhu, Stan B ^a,b   Robinson, Bruce G ^a,b   Soon, Patsy S H ^c,d,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^e INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

Author keywords

Breast cancer; microRNA; Serum

Indexed keywords

MICRORNA; MICRORNA 484; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTHY VOLUNTEERS; HUMANS; MICRORNAS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84899072306     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-200     Document Type: Article

References (28)

1. Soon PS, Kiaris H. MicroRNAs in the tumor microenvironment: big role for small players. Endocr Relat Cancer 2013, 20(5):R257-R267. 10.1530/ERC-13-0119, 23878074.
2. Kozomara A, Griffiths-Jones S. MiRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011, 39(Database issue)(Database issue):D152-D157.
3. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269. 10.1038/nrc1840, 16557279.
4. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiuni P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
5. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3(9):e3148. 10.1371/journal.pone.0003148, 2519789, 18773077.
6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006. 10.1038/cr.2008.282, 18766170.
7. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105(30):10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
8. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 2012, 14(1):R34. 10.1186/bcr3127, 3496152, 22353773.
9. Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, Vandesompele J. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008, 36(21):e143. 10.1093/nar/gkn725, 2588502, 18940866.
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
11. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010, 251(3):499-505. 10.1097/SLA.0b013e3181cc939f, 20134314.
12. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008, 28(22):6773-6784. 10.1128/MCB.00941-08, 2573297, 18794355.
13. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with Low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013, 19(13):3600-3610. 10.1158/1078-0432.CCR-12-3092, 23697990.
14. Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 2002, 62(18):5351-5357.
15. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002, 160(1):91-99. 10.1016/S0002-9440(10)64353-2, 1867150, 11786403.
16. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, Califano D, Pignata S, Losito S, Canzonieri V, Sorio R, Alder H, Wernicke D, Stoppacciaro A, Baldassarre G, Croce CM. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci 2013, 110(24):9845-9850. 10.1073/pnas.1305472110, 3683704, 23697367.
17. Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci 2013, 110(18):7413-7417. 10.1073/pnas.1304977110, 3645522, 23589849.
18. Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn S, Altmeyer P, Bechara F. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res 2013, 351(1):85-98. 10.1007/s00441-012-1514-5, 23111773.
19. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna 2008, 14(11):2348-2360. 10.1261/rna.1034808, 2578865, 18812439.
20. Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, Deroo LA, Sandler DP, Taylor JA. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res 2013, 15(3):R42. 10.1186/bcr3428, 3706791, 23705859.
21. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS-G. Identification of circulating MicroRNA signatures for breast cancer detection. Clinical Cancer Research 2013, 19(16):4477-4487. 10.1158/1078-0432.CCR-12-3401, 23797906.
22. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012, 22(3):125-132. 10.1016/j.tcb.2011.12.001, 22260888.
23. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011, 54(4):1237-1248. 10.1002/hep.24504, 3310362, 21721029.
24. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010, 12(6):R90. 10.1186/bcr2766, 3046429, 21047409.
25. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010, 119(3):586-593. 10.1016/j.ygyno.2010.07.021, 20801493.
26. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 2012, 33(4):828-834. 10.1093/carcin/bgs030, 22298638.
27. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics 2009, 25(15):1991-1993. 10.1093/bioinformatics/btp299, 19435746.
28. Järvinen TH, Liu E. Her-2/neu and topoisomerase iiα in breast cancer. Breast Cancer Res Treat 2003, 78(3):299-311. 10.1023/A:1023077507295, 12755489.